69 research outputs found

    Configuration and Digital Simulation of STATCOM utilizing 48-Pulse VSC for Reactive Power Reparation and Potential Reliability

    Get PDF
    This paper analyzes the configuration of Static Synchronous Compensator-STATCOM utilizing 48 pulse voltage source converter for reactive force reparation and voltage adjustment in force framework transmission and dispersion systems alongside the advanced development of the STATCOM utilizing 48 pulse VSC, expecting framework subjected to unsettling disturbances of real and reactive power. The 48 Pulse voltage source converter is composed with the guide of four 3-level voltage source converters exchanging at the major recurrence to create a sinusoidal yield voltage with decreased symphonies substance. The outline and computerized recreation of STATCOM has been executed in the MATLAB/Simulink stage. It is strongly evident that the outcome of reactive power reparation and voltage stabilization have been substantially improved by the proposed STATCOM configuration with 48 pulse VSC

    Traumatic acute posterior fossa subdural hematoma: A case report and review of literature

    Get PDF
    Traumatic subdural hematomas of the posterior fossa are rare but dangerous neurosurgical emergencies that require prompt diagnosis and management to avoid the uniformly poor outcome. We present a case of a teenager with severe TBI and acute subdural hematoma of the posterior fossa that deteriorated rapidly before surgery but eventually made a good recovery. We also the review the literature concerning traumatic posterior fossa subdural hematomas [PFSDH]

    Traumatic Acute Posterior Fossa Subdural Hematoma -A case report and review of literature

    Get PDF
    Abstract Traumatic subdural hematomas of the posterior fossa are rare but dangerous neurosurgical emergencies that require prompt diagnosis and management to avoid the uniformly poor outcome. We present a case of a teenager with severe TBI and acute subdural hematoma of the posterior fossa that deteriorated rapidly before surgery but eventually made a good recovery. We also the review the literature concerning traumatic posterior fossa subdural hematomas [PFSDH]

    Determination of Taguchi Grey Relation Analysis to Influence the Tool Geometry and Cutting Parameters of the Ti-6Al-4V Alloy to Achieve Better Product Quality

    Get PDF
    It may be more expensive on some system, as manufacturers frequently obtain and spread over new producing materials that are brighter and stouter—and thus a lot of fuel-effectual—it follows that cutting tool manufacturers should mature tools which will machine the new specimens and Geometry at the best attainable levels of productivity. Feasibly the mutual thread through all producing is the determination for exaggerated productivity and dependableness. As metal cutting operations become increasingly fine-tuned, the relationship between cutlery micro (cutting edge preparation) and macro (rake face topography) pure mathematics is changing into a lot of and a lot of necessary. This study intelligences the outcomes of a Turning experiment showed on the Ti–6Al–4V alloy of L9 orthogonal array on CNC Turning center with Taughi gray relative analysis. Emphases on the optimization of Turning method parameters victimization the technique to get minimum Resultant Cutting Force, Tool Wear, Tool Life, and Energy Consumption. The experimentations were performed on Ti–6Al–4V alloy block of the cutting tool of changed pure mathematics of CNMP120408-SM TN8025 of twelve metric linear unit diameter with cutting purpose one hundred forty degrees, used throughout the experimental work beneath totally different cutting conditions. Grey relative Analysis & ANOVA was castoff to total the primary necessary Cutting speed as constant of 3000Rpm, feed rate, Depth of Cut and Different Tool Geometries conditions that moving the response. The main and interaction effect of the input variables on the expected responses are investigated. The expected values and measured values are fairly Near to the Outcome one

    What controls seasonal evolution of sea surface temperature in the Bay of Bengal? Mixed layer heat budget analysis using moored buoy observations along 90°E

    Get PDF
    Author Posting. © The Oceanography Society, 2016. This article is posted here by permission of The Oceanography Society for personal use, not for redistribution. The definitive version was published in Oceanography 29, no. 2 (2016): 202–213, doi:10.5670/oceanog.2016.52.Continuous time-series measurements of near surface meteorological and ocean variables obtained from Research Moored Array for African-Asian-Australian Monsoon Analysis and Prediction (RAMA) moorings at 15°N, 90°E; 12°N, 90°E; and 8°N, 90°E and an Ocean Moored buoy Network for Northern Indian Ocean (OMNI) mooring at 18°N, 90°E are used to improve understanding of air-sea interaction processes and mixed layer (ML) temperature variability in the Bay of Bengal (BoB) at seasonal time scales. Consistent with earlier studies, this analysis reveals that net surface heat flux primarily controls the ML heat balance. The penetrative component of shortwave radiation plays a crucial role in the ML heat budget in the BoB, especially during the spring warming phase when the ML is thin. During winter and summer, vertical processes contribute significantly to the ML heat budget. During winter, the presence of a strong barrier layer and a temperature inversion (warmer water below the ML) leads to warming of the ML by entrainment of warm subsurface water into the ML. During summer, the barrier layer is relatively weak, and the ML is warmer than the underlying water (i.e., no temperature inversion); hence, the entrainment cools the mixed layer. The contribution of horizontal advection to the ML heat budget is greatest during winter when it serves to warm the upper ocean. In general, the residual term in the ML heat budget equation is quite large during the ML cooling phase compared to the warming phase when the contribution from vertical heat flux is small.WHOI buoy deployment was supported by the US Office of Naval Research (grant no. N00014- 13-10453)

    Transcriptional Analysis Implicates Endoplasmic Reticulum Stress in Bovine Spongiform Encephalopathy

    Get PDF
    Bovine spongiform encephalopathy (BSE) is a fatal, transmissible, neurodegenerative disease of cattle. To date, the disease process is still poorly understood. In this study, brain tissue samples from animals naturally infected with BSE were analysed to identify differentially regulated genes using Affymetrix GeneChip Bovine Genome Arrays. A total of 230 genes were shown to be differentially regulated and many of these genes encode proteins involved in immune response, apoptosis, cell adhesion, stress response and transcription. Seventeen genes are associated with the endoplasmic reticulum (ER) and 10 of these 17 genes are involved in stress related responses including ER chaperones, Grp94 and Grp170. Western blotting analysis showed that another ER chaperone, Grp78, was up-regulated in BSE. Up-regulation of these three chaperones strongly suggests the presence of ER stress and the activation of the unfolded protein response (UPR) in BSE. The occurrence of ER stress was also supported by changes in gene expression for cytosolic proteins, such as the chaperone pair of Hsp70 and DnaJ. Many genes associated with the ubiquitin-proteasome pathway and the autophagy-lysosome system were differentially regulated, indicating that both pathways might be activated in response to ER stress. A model is presented to explain the mechanisms of prion neurotoxicity using these ER stress related responses. Clustering analysis showed that the differently regulated genes found from the naturally infected BSE cases could be used to predict the infectious status of the samples experimentally infected with BSE from the previous study and vice versa. Proof-of-principle gene expression biomarkers were found to represent BSE using 10 genes with 94% sensitivity and 87% specificity

    Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

    Get PDF
    Background: Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes for patients with metastatic prostate cancer. Here, we aimed to evaluate long-term outcomes and test whether combining enzalutamide with abiraterone and androgen deprivation therapy improves survival. Methods: We analysed two open-label, randomised, controlled, phase 3 trials of the STAMPEDE platform protocol, with no overlapping controls, conducted at 117 sites in the UK and Switzerland. Eligible patients (no age restriction) had metastatic, histologically-confirmed prostate adenocarcinoma; a WHO performance status of 0–2; and adequate haematological, renal, and liver function. Patients were randomly assigned (1:1) using a computerised algorithm and a minimisation technique to either standard of care (androgen deprivation therapy; docetaxel 75 mg/m2 intravenously for six cycles with prednisolone 10 mg orally once per day allowed from Dec 17, 2015) or standard of care plus abiraterone acetate 1000 mg and prednisolone 5 mg (in the abiraterone trial) orally or abiraterone acetate and prednisolone plus enzalutamide 160 mg orally once a day (in the abiraterone and enzalutamide trial). Patients were stratified by centre, age, WHO performance status, type of androgen deprivation therapy, use of aspirin or non-steroidal anti-inflammatory drugs, pelvic nodal status, planned radiotherapy, and planned docetaxel use. The primary outcome was overall survival assessed in the intention-to-treat population. Safety was assessed in all patients who started treatment. A fixed-effects meta-analysis of individual patient data was used to compare differences in survival between the two trials. STAMPEDE is registered with ClinicalTrials.gov (NCT00268476) and ISRCTN (ISRCTN78818544). Findings: Between Nov 15, 2011, and Jan 17, 2014, 1003 patients were randomly assigned to standard of care (n=502) or standard of care plus abiraterone (n=501) in the abiraterone trial. Between July 29, 2014, and March 31, 2016, 916 patients were randomly assigned to standard of care (n=454) or standard of care plus abiraterone and enzalutamide (n=462) in the abiraterone and enzalutamide trial. Median follow-up was 96 months (IQR 86–107) in the abiraterone trial and 72 months (61–74) in the abiraterone and enzalutamide trial. In the abiraterone trial, median overall survival was 76·6 months (95% CI 67·8–86·9) in the abiraterone group versus 45·7 months (41·6–52·0) in the standard of care group (hazard ratio [HR] 0·62 [95% CI 0·53–0·73]; p<0·0001). In the abiraterone and enzalutamide trial, median overall survival was 73·1 months (61·9–81·3) in the abiraterone and enzalutamide group versus 51·8 months (45·3–59·0) in the standard of care group (HR 0·65 [0·55–0·77]; p<0·0001). We found no difference in the treatment effect between these two trials (interaction HR 1·05 [0·83–1·32]; pinteraction=0·71) or between-trial heterogeneity (I2 p=0·70). In the first 5 years of treatment, grade 3–5 toxic effects were higher when abiraterone was added to standard of care (271 [54%] of 498 vs 192 [38%] of 502 with standard of care) and the highest toxic effects were seen when abiraterone and enzalutamide were added to standard of care (302 [68%] of 445 vs 204 [45%] of 454 with standard of care). Cardiac causes were the most common cause of death due to adverse events (five [1%] with standard of care plus abiraterone and enzalutamide [two attributed to treatment] and one (<1%) with standard of care in the abiraterone trial). Interpretation: Enzalutamide and abiraterone should not be combined for patients with prostate cancer starting long-term androgen deprivation therapy. Clinically important improvements in survival from addition of abiraterone to androgen deprivation therapy are maintained for longer than 7 years. Funding: Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, Janssen, and Astellas
    • …
    corecore